YouJizz porno atasehir escort bostanci escort erenkoy escort goztepe escort kadikoy Escort kartal Escort maltepe Escort suadiye Escort uskudar Escort umraniye Escort kartal escort bostanci escort atasehir escort kadikoy escort kurtkoy escort tuzla escort erenkoy escort beykoz escort umraniye escort pendik escort kadikoy escort maltepe escort antalya escort konya escort

Market Research Reports and Industry Reports

Market Access Impact (EU5) [MS]

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS



Market barriers affect nearly 15% of multiple sclerosis prescriptions in the EU5

In the EU5 countries, market barriers affect a modest 15% of multiple sclerosis prescriptions, but theyre giving market share to most of the brands we surveyed. These market share gains go to 7 of the 11 brands we surveyed, putting the market leaders even further ahead. Meanwhile some brands have a bigger problem: doctors arent prescribing them at the same rates as other treatments.

Market Access Impact: Multiple Sclerosis (EU5) shows you how widely prescribed your brand is, and reveals how 7 barriers affect your market share. Youll learn how much share you win and lose, who you take share from, and who gets your lost share.

Based on a survey of 150 neurologists from the key EU5 markets (France, Germany, Italy, Spain and the UK), the report covers 11 major therapies from Genzyme, Biogen, Sanofi, Bayer, Teva, Novartis, Merck Group, and AbbVie/Biogen.

Not your market? Click here to see the US report






Top Takeaways

Barriers affect nearly 15% of prescriptions. Most barriers have a more or less equal overall impact, but each one affects some brands more than others.
Most brands gain share. 7 of the 11 surveyed brands lose market gain share because of barriers, and these gains are significant for the leading brands.
One brand has a big lead. Despite the fact that this brand is only the sixth most prescribed brand, barriers are proving to be a huge positive as it gains the most share than any other brand.
2 barriers are holding most brands back. All surveyed neurologists opine that they cant prescribe many of the brands due to patient related issues.
Awareness is good for all brands. Very few neurologists havent heard of the brands we surveyed, but willingness to try data might be surprising for some brands.

Insight into 11 Major Asthma/COPD Drugs

Aubagio (teriflunomide; Sanofi)
Avonex (interferon beta-1a; Biogen)
Betaferon (interferon-beta-1; Bayer)
Copaxone (glatiramer acetate; Teva)
Gilenya (fingolimod; Novartis)
Lemtrada (alemtuzumab; Genzyme)
Plegridy (peginterferon beta-1a; Biogen)
Rebif (interferon beta-1a; Merck Group)
Tecfidera (dimethyl fumarate; Biogen)
Tysabri (natalizumab; Biogen)
Zinbryta (daclizumab; AbbVie/Biogen)

Exploring Market Access Barriers

Market Access Impact: Multiple Sclerosis (EU5) explores key issues affecting drug manufacturers. Youll learn:

How barriers affect market access:

What brands do doctors prescribe the most?
How many prescriptions do barriers affect?
Which barriers have the biggest impact?

How barriers affect your brand:

How many doctors prescribe your brand? How many dont, but would consider it?
Why dont doctors prescribe your brand? What do they prescribe instead?
Which competing brands does your brand take market share from?


A Report Based on Expert Knowledge

We surveyed 150 neurologists30 from each EU5 country (France, Italy, Germany, Spain, UK)chosen from the largest community of validated physicians in the world.

All respondents have:

Been practicing for 2+ years
Prescribed at least one of the listed products
Seen at least 5 patients with asthma and/or COPD in total in the last month

We conducted the survey between July 3rd and 13th, 2017.

MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If youre not completely satisfied, well refund your money. Guaranteed.


About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your companys success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


1.What are market barriers?
2.About this report
3.About the survey
4.Brands included in the survey
5.Executive summary

Global Low-emissivity Glass Sales Market Report 2017

In this report, the global Low-emissivity Glass market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing

USD 4000View Report

Global Low Intensity Infrared Tube Heaters Sales Market Report 2017

In this report, the global Low Intensity Infrared Tube Heaters market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end

USD 4000View Report

Key Success Factors in Pricing, Reimbursement and Market Access

Key Success Factors in Pricing, Reimbursement and Market AccessNovel pricing and reimbursement models are shaping the uptake of medicines. Yet the market access goalposts keep being moved as payer policies,

USD 695View Report

Market Access Impact (EU5) [NSCLC]

Eliminating prescription barriers could break the tie at the top of the marketThe two leading brands in the EU5 non-small cell lung cancer (NSCLC) market are tied for market share,

USD 5145View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)


+91 9987 2952 42

CHOOSE FORMAT

  • PDF    USD 5145
  • Enterprise Wide Licence    USD 7725
$ 5145

Reports Details

Published Date : Jul 2017
Country :Global
Category :Healthcare
Publisher :FirstWord Dossier
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube